GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (MEX:NVO) » Definitions » EV-to-FCF

Novo Nordisk AS (MEX:NVO) EV-to-FCF : 38.85 (As of Jan. 18, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Novo Nordisk AS EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Novo Nordisk AS's Enterprise Value is MXN7,228,475 Mil. Novo Nordisk AS's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was MXN186,072 Mil. Therefore, Novo Nordisk AS's EV-to-FCF for today is 38.85.

The historical rank and industry rank for Novo Nordisk AS's EV-to-FCF or its related term are showing as below:

MEX:NVO' s EV-to-FCF Range Over the Past 10 Years
Min: 13.19   Med: 28.81   Max: 89.72
Current: 37.87

During the past 13 years, the highest EV-to-FCF of Novo Nordisk AS was 89.72. The lowest was 13.19. And the median was 28.81.

MEX:NVO's EV-to-FCF is ranked worse than
66.06% of 548 companies
in the Drug Manufacturers industry
Industry Median: 23.77 vs MEX:NVO: 37.87

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-01-18), Novo Nordisk AS's stock price is MXN1639.33. Novo Nordisk AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was MXN55.870. Therefore, Novo Nordisk AS's PE Ratio (TTM) for today is 29.34.


Novo Nordisk AS EV-to-FCF Historical Data

The historical data trend for Novo Nordisk AS's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS EV-to-FCF Chart

Novo Nordisk AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.79 33.49 35.85 32.94 44.41

Novo Nordisk AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.73 44.41 78.52 67.74 51.98

Competitive Comparison of Novo Nordisk AS's EV-to-FCF

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk AS's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's EV-to-FCF falls into.



Novo Nordisk AS EV-to-FCF Calculation

Novo Nordisk AS's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=7228474.638/186072.482
=38.85

Novo Nordisk AS's current Enterprise Value is MXN7,228,475 Mil.
Novo Nordisk AS's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN186,072 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novo Nordisk AS  (MEX:NVO) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Novo Nordisk AS's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1639.33/55.870
=29.34

Novo Nordisk AS's share price for today is MXN1639.33.
Novo Nordisk AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN55.870.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Novo Nordisk AS EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk AS Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.